Document:

<PAGE>
                                                                     EXHIBIT 4.4

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR
OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT
OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.

                            WARRANT TO PURCHASE STOCK

Corporation: GENITOPE CORPORATION, a Delaware corporation
Number of Shares: 9,167
Class of Stock: Series C Preferred
Initial Exercise Price: $1.50 per Share
Issue Date: July 19, 1999
Expiration Date: The longer of (i) 10 years from the Issue Date or (ii) 7 years
from the date of the initial public offering of the Company

         THIS WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for
other good and valuable consideration, SILICON VALLEY BANK ("Holder") is
entitled to purchase the number at fully paid and nonassessable shares of the
class of securities (the "Shares") of the corporation (the "Company") at the
initial exercise price per Share (the "Warrant Price") all as set forth above
and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions
and upon the terms and conditions set forth in this Warrant.

ARTICLE 1 - EXERCISE

                  1.1 Method of Exercise. Holder may exercise this Warrant by
delivering a duly executed Notice of Exercise in substantially the form attached
as Appendix 1 to the principal office of the Company. Unless Holder is
exercising the conversion right set forth in Section 1.2, Holder shall also
deliver to the Company a check for the aggregate Warrant Price for the Shares
being purchased.

                  1.2 Conversion Right. In lieu of exercising this Warrant as
specified in Section 1.1, Holder may from time to time convert this Warrant, in
whole or in part, into a number of Shares determined by dividing (a) the
aggregate fair market value of the Shares or other securities otherwise issuable
upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares
shall be determined pursuant to Section 1.4.

                  1.3 Intentionally Omitted

                  1.4 Fair Market Value. If the Shares are traded in a public
market, the fair market value of the Shares shall be the closing price of the
Shares (or the closing price of the Company's stock into which the Shares are
convertible) reported for the business day immediately before Holder delivers
its Notice of Exercise to the Company. If the Shares are not traded in a public
market, the Board of Directors of the Company shall determine fair market value
in its reasonable good faith judgment. The foregoing notwithstanding, if Holder
advises the Board of Directors in writing that Holder disagrees with such
determination, then the Company and Holder shall promptly agree upon a reputable
investment banking firm to undertake such valuation. If the valuation of such
investment banking firm is greater than that determined by the Board of
Directors, then all fees and expenses of such investment banking firm shall be
paid by the Company. In all other circumstances, such fees and expenses shall be
paid by Holder.

                  1.5 Delivery of Certificate and New Warrant. Promptly after
Holder exercises or converts this Warrant, the Company shall deliver to Holder
certificates for the Shares acquired and, if this

                                       1.
<PAGE>

Warrant has not been fully exercised or converted and has not expired, a new
Warrant representing the Shares not so acquired.

                  1.6 Replacement of Warrants. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company
or, in the case of mutilation, on surrender and cancellation of this Warrant,
the Company at its expense shall execute and deliver, in lieu of this Warrant, a
new warrant of like tenor.

                  1.7 Repurchase on Sale, Merger, or Consolidation of the
Company.

                           1.7.1 "Acquisition". For the purpose of this Warrant,
"Acquisition" means any sale, license, or other disposition of all or
substantially all of the assets of the Company, or any reorganization,
consolidation, or merger of the Company where the holders of the Company's
securities before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity after the transaction.

                           1.7.2 Assumption of Warrant. Upon the closing of any
Acquisition, the successor entity shall assume the obligations of this Warrant,
and this Warrant shall be exercisable for the same securities, cash, and
property as would be payable for the Shares issuable upon exercise of the
unexercised portion of this Warrant as if such Shares were outstanding on the
record date for the Acquisition and subsequent closing. The Warrant Price shall
be adjusted accordingly.

                           1.7.3 Purchase Right. Notwithstanding the foregoing,
at the election of Holder, the Company shall purchase the unexercised portion of
this Warrant for cash upon the closing of any Acquisition for an amount equal to
(a) the fair market value of any consideration that would have been received by
Holder in consideration of the Shares had Holder exercised the unexercised
portion of this Warrant immediately before the record date for determining the
shareholders entitled to participate in the proceeds of the Acquisition, less
(b) the aggregate Warrant Price of the Shares, but in no event less than zero.

ARTICLE 2 - ADJUSTMENTS TO THE SHARES

                  2.1 Stock Dividends, Splits, Etc. If the Company declares or
pays a dividend on its common stock (or the Shares if the Shares are securities
other than common stock) payable in common stock, or other securities,
subdivides the outstanding common stock into a greater amount of common stock,
or, if the Shares are securities other than common stock, subdivides the Shares
in a transaction that increases the amount of common stock into which the Shares
are convertible, then upon exercise of this Warrant, for each Share acquired,
Holder shall receive, without cost to Holder, the total number and kind of
securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend or subdivision occurred.

                  2.2 Reclassification, Exchange or Substitution. Upon any
reclassification, exchange, substitution, or other event that results in a
change of the number and/or class of the securities issuable upon exercise or
conversion of this Warrant, Holder shall be entitled to receive, upon exercise
or conversion of this Warrant, the number and kind of securities and property
that Holder would have received for the Shares if this Warrant had been
exercised immediately before such reclassification, exchange, substitution, or
other event. Such an event shall include any automatic conversion of the
outstanding or issuable securities of the Company of the same class or series as
the Shares to common stock pursuant to the terms of the Company's Articles of
Incorporation upon the closing of a registered public offering of the Company's
common stock. The Company or its successor small promptly issue to Holder a new
warrant for such new securities or other property. The new Warrant shall provide
for adjustments which shall be as nearly equivalent as may be practicable to the
adjustments provided for in this Article 2 including, without limitation,
adjustments to the Warrant Price and to the number of securities or property
issuable upon exercise of the new Warrant. The provisions of this Section 2.2
shall similarly apply to successive reclassifications, exchanges, substitutions,
or other events

                                       2.
<PAGE>

                  2.3 Adjustments for Combinations, Etc. If the outstanding
Shares are combined or consolidated, by reclassification or otherwise, into a
lesser number of shares, the Warrant Price shall be proportionately increased.

                  2.4 Adjustments for Diluting Issuances. The Warrant Price and
the number of Shares issuable upon exercise of this Warrant or, if the Shares
are Preferred Stock, the number of shares of common stock issuable upon
conversion of the Shares, shall be subject to adjustment, from time to time in
the manner set forth in the Company's Amended and Restated Certificate of
Incorporation dated March 18, 1999.

                  2.5 No Impairment. The Company shall not, by amendment of its
Articles of Incorporation or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of
the terms to be observed or performed under this Warrant by the Company, but
shall at all times in good faith assist in carrying out of all the provisions of
this Article 2 and in taking all such action as may be necessary or appropriate
to protect Holder's rights under this Article against impairment. If the Company
takes any action affecting the Shares or its common stock other than as
described above that adversely affects Holder's rights under this Warrant, the
Warrant Price shall be adjusted downward and the number of Shares issuable upon
exercise of this Warrant shall be adjusted upward in such a manner that the
aggregate Warrant Price of this Warrant is unchanged.

                  2.6 Fractional Shares. No fractional Shares shall be issuable
upon exercise or conversion of the Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional share interest
arises upon any exercise or conversion of the Warrant, the Company shall
eliminate such fractional share interest by paying Holder amount computed by
multiplying the fractional interest by the fair market value of a full Share.

                  2.7 Certificate as to Adjustments. Upon each adjustment of the
Warrant Price, the Company at its expense shall promptly compute such adjustment
and furnish Holder with a certificate of its Chief Financial Officer setting
forth such adjustment and the facts upon which such adjustment is based. The
Company shall, upon written request, furnish Holder a certificate setting forth
the Warrant Price in upon the date thereof and the series of adjustments leading
to such Warrant Price.

ARTICLE 3 - REPRESENTATIONS AND COVENANTS OF THE COMPANY.

                  3.1 Representations and Warranties. The Company hereby
represents and warrants to the Holder as follows:

                           (a) The initial Warrant Price referenced on the first
page of this Warrant is not greater than (i) the price per Share at which the
Shares were last issued in an arms-length transaction in which at least $500,000
of the Shares were sold and (ii) the fair market value of the Shares as at the
date of this Warrant.

                           (b) All Shares which may be issued upon the exercise
of the purchase right represented by this Warrant, and all securities, if any,
issuable upon conversion of the Shares, shall, upon issuance, be duly authorized
validly issued, fully paid and nonassessable, and free of any liens and
encumbrances except for restrictions an transfer provided for herein or under
applicable federal and state securities laws.

                           (c) The Capitalization tools attached hereto is true
and correct.

                  3.2 Notice of Certain Events. If the Company proposes at any
time (a) to declare any dividend or distribution upon its common stock, whether
in cash, property, stock, or other securities and whether or not a regular cash
dividend; (b) to offer for subscription pro rata to the holders of any class or
series of its stock any additional Shares of stock of any class or series or
other rights; (c) to effect any reclassification or recapitalization of common
stock; (d) to merge or consolidate with or into any other

                                       3.
<PAGE>
corporation, or sell, lease, license, or convey all or substantially all of its
assets, or to liquidate, dissolve or wind up; or (e) offer holders of
registration rights the opportunity to participate in an underwritten public
offering of the company's securities for cash, then, in connection with each
such event, the Company shall give Holder (1) at least 20 days prior written
notice of the date on which a record will be taken for such dividend,
distribution, or subscription rights (and specifying the date on which the
holders of common stock will be entitled thereto) or for determining rights to
vote, if any, in respect of the matters referred to in (c) and (d) above; (2) in
the case of the matters referred to in (c) and (d) above at least 20 days prior
written notice of the date when the same will take place (and specifying the
date on which the holders of common stock will be entitled to exchange their
common stock for or other property deliverable upon the occurrence of such
event); and (3) in the case of the matter referred to in (a) above, the same
notice as is given to the holders of such registration rights.

                  3.3 Information Rights. So long as the Holder holds this
Warrant and/or any of the Shares, the Company shall deliver to the Holder (a)
promptly after mailing, copies of all notices or other written communications to
the shareholders of the Company, (b) within ninety (90) days after the end of
each fiscal year of the Company, the annual audited financial statements of the
Company certified by independent public accountants of recognized standing and
(c) such other financial statements required under and in accordance with any
loan documents between Holder and the Company (or if there are no such
requirements [or if the subject loan(s) no longer are outstanding]), then within
forty-five (45) days after the end of each of the first three quarters of each
fiscal year, the Company's quarterly, unaudited financial statements.

                  3.4 Registration Under Securities Act of 1933, as amended. The
Company agrees that the Shares or, if the Shares are convertible into common
stock of the Company, such common stock, shall be subject to the registration
rights set forth in the Investor Rights Agreement dated ___________.

ARTICLE 4 - MISCELLANEOUS.

                  4.1 Term; Notice of Expiration. This Warrant is exercisable,
in whole or in part, at any time and from time to time on or before the
Expiration Date set forth above. The Company shall give Holder written notice of
Holder's right to exercise this Warrant in the form attached as Appendix 2 not
more than 90 days and not less than 30 days before the Expiration Date. If the
notice is not so given, the Expiration Date shall automatically be extended
until 30 days after the date the Company delivers the notice to holder.

                  4.2 Legends. This Warrant and the Shares (and the Securities
issuable directly or indirectly, upon conversion of the Shares, if any) shall be
imprinted with a legend in substantially the following form:

         THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
         AS AMENDED, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED
         WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO
         RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
         CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

                  4.3 Compliance with Securities Laws on Transfer. This Warrant
and the Shares issuable upon exercise this Warrant (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) may not be
transferred or assigned in whole or in part without compliance with applicable
federal and state securities laws by the transferor and the transferee
(including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Holder to provide am
opinion of counsel if the transfer is to an affiliate of Holder or if there is
no material question as to the availability of current information as referenced
in Rule 144(c). Holder represents that it has complied with Rule 144(d) and (e)
in reasonable detail, the selling broker represents that it has complied with
Rule 144(f), and the Company is provided with a copy of Holder's notice of
proposed sale.

                                       4.
<PAGE>

                  4.4 Transfer Procedure. Subject to the provisions of Section
4.3 Holder may transfer all or part of this Warrant or the Shares issuable upon
exercise of this Warrant (or the securities issuable, directly or indirectly,
upon conversion of the Shares, if any) at any time to Silicon Valley Bancshares
or The Silicon Valley Bank Foundation, or, to any other transferee by giving the
Company notice of the portion of the Warrant being transferred setting forth the
name, address and taxpayer identification number of the transferee and
surrendering this Warrant to the Company for reissuance to the transferee(s)
(and Holder if applicable). Unless the Company is filing financial information
with the SEC pursuant to the Securities Exchange Act of 1934, the Company shall
have the right to refuse to transfer any portion of this Warrant to any person
who directly competes with the Company.

                  4.5 Notices. All notices and other communications from the
Company to the Holder, or vice versa, shall be deemed delivered and effective
when given personally or mailed by first-class registered or certified mail,
postage prepaid, at such address as may have been furnished to the Company or
the Holder, as the case may be, in writing by the Company or such holder from
time to time.

                  4.6 Waiver. This Warrant and any term hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination
is sought.

                  4.7 Attorneys Fees. In the event of any dispute between the
parties concerning the terms and provisions of this Warrant, the party
prevailing in such dispute shall be entitled to collect from the other party all
costs incurred in such dispute, including reasonable attorneys' fees.

                  4.8 Governing Law. This Warrant shall be governed by and
construed in accordance with the laws of the State of California, without giving
effect to its principles regarding conflicts of law.

                                      "COMPANY"

                                      GENITOPE CORPORATION

                                      By:   /s/ Milton B. McColl
                                            ------------------------------------

                                      Name: Milton B. McColl
                                            ------------------------------------
                                            (Print)
                                      Title:
                                            ------------------------------------
                                             Chairman of the Board, President or
                                             Vice President

                                      By:   /s/ Diane Ingolia
                                            ------------------------------------

                                      Name: Diane Ingolia
                                           -------------------------------------
                                           (Print)
                                      Title:
                                           -------------------------------------
                                           Chief Financial Officer, Secretary,
                                           Assistant Treasurer or Assistant
                                           Secretary

                                       5.
<PAGE>

                                   APPENDIX 1

                               NOTICE OF EXERCISE

         1. The undersigned hereby elects to purchase _________ shares of the
Common/Preferred Series __ [Strike one] Stock of GENITOPE CORPORATION pursuant
to the terms of the attached Warrant, and tenders herewith payment of the
purchase price of such shares in full,

         1. The undersigned hereby elects to convert the attached Warrant into
Shares/cash [strike one] in the manner specified in the Warrant. This conversion
is exercised with respect to ________________ of the Shares covered by the
Warrant.

         [Strike paragraph that does not apply.]

         2. Please issue a certificate or certificates representing said shares
in the name of the undersigned or in such other name as is specified below:

                  ------------------------------------
                            (Name)

                  ------------------------------------

                  ------------------------------------
                           (Address)

         3. The undersigned represents it is acquiring the shares solely for its
own account and not as a nominee for any other party and not with a view toward
the resale or distribution thereof except in compliance with applicable
securities laws.

                                            ------------------------------------
                                                     (Signature)

------------------------------
           (Date)

                                       1.

<PAGE>

                                   APPENDIX 2

                     Notice that Warrant is About to Expire

                              -------------, -----

(Name of Holder)

(Address of Holder)

Attn:  Chief Financial Officer

Dear _________________________:

         This is to advise you that the Warrant issued to you described below
will expire on __________________________________, 19______.

         Issuer:

         Issue Date:

         Class of Security Issuable:

         Exercise Price per Share:

         Number of Shares Issuable:

         Procedure for Exercise:

         Please contact [name of contact person at (phone number)] with any
questions you may have concerning exercise of the Warrant. This is your only
notice of pending expiration.

                                            ------------------------------------
                                            (Name of Issuer)

                                            By:

                                            ------------------------------------

                                            Its:

                                            ------------------------------------<PAGE>
                                                                    EXHIBIT 10.2

                             (GENITOPE LETTERHEAD)

                                             21 January 2002

Fred Kurland
4213 Los Palos Avenue
Palo Alto, CA 94306

RE: EMPLOYMENT TERMS

Dear Fred:

Genitope Corporation (the "Company") is pleased to offer you a position with the
Company, on the following terms:

You will be Vice President of Finance and Chief Financial Officer, starting no
later than February 25, 2002. Your first day of work will be your "Employment
Date." You will be responsible for all finance functions as well as facilities
and IT functions at the Company. You will report to the CEO, Dan Denney. Your
position will be full-time. Your compensation will be $20,000 per month
($240,000 per year), less standard payroll deductions and withholdings. You will
be paid according to the Company's regular payroll schedule. The Company will
reimburse you for the monthly charges and all business related calls on a
cellular telephone and for an annual airline lounge membership. The Company will
subscribe to BioCentury and provide a copy to you.

Subject to the approval of the Board of Directors, upon commencement of your
employment, the Company will grant you a nonstatutory stock option to purchase
220,000 shares of Company common stock (the "Option") pursuant to the Company's
1996 Stock Option Plan (the "Plan") at an exercise price equal to the then fair
market value of a share of the Company's common stock on the date of grant. The
current fair market value of the Company's common stock is $0.40 per share.

Your Option will be subject to the Company's standard vesting schedule and will
have a term of ten years, measured from the grant date. Vesting will begin on
the Employment Date if that date is earlier than the Option grant date.
Twenty-five percent of the shares (55,000 shares) will vest after one year of
employment, and the remaining shares will vest monthly (4583 shares) over the
next three years, provided you remain actively employed with the Company. Your
Option will provide that you may elect to exercise any or all shares subject to
the Option at any time during the term of the Option, subject to the Company's
right of first refusal and right of repurchase, as provided in the Plan and
related documents.

<PAGE>

Fred Kurland
January 17, 2002
Page 2

The Company shall provide a full recourse loan to you, up to an amount of
$22,000, for the sole purpose of your exercise of a portion of the Option (the
"Loan"), and such Loan shall be secured by the shares of Common Stock so
purchased by you.

In the event that your employment terminates for any reason prior to completion
of the four-year vesting schedule applicable to the Option, the Company shall
have the right to purchase from you any unvested shares of Common Stock
purchased through Option exercise at a purchase price equal to the exercise
price per share of the Option, payable at the Company's choice in either cash or
cancellation of indebtedness on the Loan. Interest paid on the principal sum of
the Loan shall be simple interest accrued from the date of extension of the Loan
at an annual rate determined by Silicon Valley Bank at the time of extension of
the Loan and subject to confirmation by the Company's accountants as a market
rate of interest for financial accounting purposes. The principal amount and all
interest shall be due and payable in full forty-eight (48) months from the date
of extension of the Loan; provided, however, that in the event you resign your
employment with the Company for any reason or your employment with the Company
is terminated for any reason, including, without limitation, termination with or
without cause, or termination due to disability or death, or job elimination,
prior to payment in full of the Loan, the Loan shall be accelerated and all
remaining unpaid principal and all interest shall become due and payable thirty
(30) days after such resignation or termination. The Company shall provide you
with the necessary documents to execute the Loan and exercise the Option.

Should your status as an employee terminate due to an involuntary termination
without Cause or voluntary termination for Good Reason following a Change of
Control of the Company, as such capitalized terms are defined in the Genitope
Corporation 1996 Stock Option Plan, a copy of which is enclosed, in either case
within thirteen (13) months after the effective date of the Change in Control,
you will be paid an amount equal to twelve (12) months of your base salary,
subject to standard payroll deductions and withholdings, and paid in equal
amounts over twelve (12) months on the Company's normal payroll schedule, and
the Company shall provide you with continued coverage under the Company's
health, dental and vision plans as if you remained an active employee for twelve
(12) months, provided that you elect COBRA continuation coverage. Such continued
health coverage shall count toward the eighteen (18) month COBRA continuation
period. In addition, the Company shall pay your targeted bonus if, for the year
in which such termination occurs, a bonus would have been payable to you if your
employment had not terminated, but such bonus payment shall not be made until
active employees are paid their bonuses. Should you accept another full-time
position elsewhere at any time during the 12-month period, the Company will have
no further obligation to make such salary or bonus payments or to provide such
continued health, dental and vision coverage, although you will have the right
to continued health coverage at your own expense in accordance with COBRA.
Should a Change of Control occur after two or more years from the date of grant
of the Option, then the vesting and exercisability of the Option shall be
accelerated as to one hundred percent (100%) of the then unvested shares of
stock subject to the Option. All future option grants will be subject to the
provisions of the Genitope Corporation 1996 Stock Option Plan and not the
provisions of the preceding sentence.

<PAGE>

Fred Kurland
January 17, 2002
Page 3

You will be eligible for standard Company benefits. The Company may add to,
delete or modify compensation and benefits from time to time in its discretion
without advance notice. Your health benefits will be available following a
mandatory wait period, and participation in the Company 401 (k) plan will be
available following a 90-day mandatory wait period. During the wait period for
health benefits, the Company will pay to you the premium amount that it would
have paid on your behalf had you been covered under the Company's health plan
during that period. As a Company employee, you will be expected to abide by the
Company's policies and procedures and sign the Company's Proprietary Information
and Inventions Agreement, a copy of which is enclosed.

Your employment relationship with the Company is at-will. You may terminate your
employment with the Company at any time and for any reason whatsoever simply by
notifying the Company. Likewise, the Company may terminate your employment at
any time with or without cause or advance notice. This at-will employment
relationship cannot be changed except in writing, signed by a Company officer.

This letter, the Proprietary Information and Inventions Agreement, and the Loan,
stock purchase and stock option documents together contain the entire agreement
between you and the Company concerning your employment relationship. They cannot
be modified except in an agreement signed by me, and they supersede any other
representations or promises made to you by anyone, whether oral or written.

This offer is valid until midnight January 22, 2002. If you have any questions,
please feel free to contact us. If these terms are acceptable to you, please
sign below and return it to me. We look forward to your favorable reply and to
working with you.

Sincerely,                                   ACCEPTED:

/s/ Dan W. Denney, Jr.                       /s/ Fred Kurland
-------------------------                    -------------------------
Dan W. Denney, Jr., Ph.D.                    Fred Kurland
Chairman & CEO

                                             -------------------------
                                             Date

Enclosures

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]